Linker Information
General Information of This Linker
| Linker ID |
LIN0HUDNI
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
T800
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C27H37N5O6
|
|||||
| Isosmiles |
O=C([C@@H](NC([C@H](C(C)C)NC(CCCCCN1C(C=CC1=O)=O)=O)=O)C)NC2=CC=C(CO)C([C]NC)=C2
|
|||||
| InChI |
InChI=1S/C27H37N5O6/c1-17(2)25(31-22(34)8-6-5-7-13-32-23(35)11-12-24(32)36)27(38)29-18(3)26(37)30-21-10-9-19(16-33)20(14-21)15-28-4/h9-12,14,17-18,25,28,33H,5-8,13,16H2,1-4H3,(H,29,38)(H,30,37)(H,31,34)/t18-,25-/m0/s1
|
|||||
| InChIKey |
LWMKNYXUYFYLFC-BVZFJXPGSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
527.622
|
Polar area
|
156.94
|
||
|
Complexity
|
992.4739502
|
xlogp Value
|
0.85459
|
|||
|
Heavy Count
|
38
|
Rot Bonds
|
15
|
|||
|
Hbond acc
|
7
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AMT-562 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must be ≥18 years with histologically confirmed unresectable advanced solid tumors, prior systemic therapy failure, ECOG 0-1, adequate organ function, and at least one measurable lesion. Key exclusions include CNS metastasis, unresolved toxicities from prior therapy, active infections, recent major surgery or radiotherapy, significant cardiac disease, or concurrent investigational trial participation. Pregnancy, substance abuse, and uncontrolled medical/psychiatric conditions also disqualify candidates.
Click to Show/Hide
|
||||
| Administration Dosage |
Administered AMT-562 for injection intravenously
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06199908 | Clinical Status | PHASE1 | ||
| Clinical Description |
First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study assesses safety endpoints including Dose Limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs), evaluated for type, incidence, and severity over a 24-month timeframe.
|
||||
| Other Endpoint |
Pharmacokinetic parameters such as Cmax, Tmax, AUC, t1/2, and Anti-Drug Antibodies (ADAs) are measured, alongside efficacy outcomes including ORR, DCR, PFS, TTR, and DOR, all assessed per RECIST v1.1 over 24 months.
|
||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.80% | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 mg/kg, day 1) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-200930) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-361319) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Squamous cell carcinoma PDX model (PDX: PDX-361318) | ||||
References